Related Experiment Videos
Abstract:
The FDA approved the antiandrogen apalutamide for the treatment of men with nonmetastatic, castration-resistant prostate cancer, the first drug for these patients greenlighted by the agency. Data from the definitive trial of apalutamide, presented at the 2018 Genitourinary Cancers Symposium, showed that the drug prolonged metastasis-free survival by more than 2 years compared with placebo. Data on the related drug enzalutamide, also presented at the symposium, showed that that drug led to dramatic improvements in metastasis-free survival, too.
Insights
The FDA approved apalutamide, an antiandrogen, for nonmetastatic castration-resistant prostate cancer. This new treatment significantly prolonged metastasis-free survival in clinical trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- The U.S. Food and Drug Administration (FDA) has approved apalutamide, a novel antiandrogen medication.
- This approval marks the first time a drug has been specifically greenlighted for men diagnosed with nonmetastatic, castration-resistant prostate cancer.
Discussion:
- Clinical trial data presented at the 2018 Genitourinary Cancers Symposium demonstrated that apalutamide therapy extended metastasis-free survival by over two years when compared to a placebo.
- The study also highlighted comparable significant improvements in metastasis-free survival for the related drug enzalutamide, also presented at the symposium.
Key Insights:
- Apalutamide represents a significant therapeutic advancement for patients with nonmetastatic castration-resistant prostate cancer.
- The drug's efficacy in prolonging metastasis-free survival underscores its clinical value.
Outlook:
- Further research may explore apalutamide's role in earlier stages of prostate cancer or in combination therapies.
- The success of apalutamide and enzalutamide may pave the way for additional targeted therapies in prostate cancer treatment.